გამოგვყევი
GE
GE

Life4me+-ის ერთ-ერთი მთავარი მიზანია აივ, სხვა სგგი, ჰეპატიტი C და ტუბერკულოზის ახალი შემთხვევების პრევენცია.

აპლიკაცია ეხმარება აივ დადებით პირებს ექიმებთან ანონიმური კომუნიკაციის დამყარებაში. ეს ყველაფერი დაგეხმარებათ ორგანიზება გაუკეთოთ მედიკამენტების მიღების განრიგს და დააყენოთ ფარული და პერსონალიზებული შეხსენებები.

ყველა სიახლე

არქივი

✕
25 სექტემბერი 2018
7246
American patients with hepatitis C will be available branded generics Gilead

American patients with hepatitis C will be available branded generics Gilead

On Monday, September 24, the American biopharmaceutical company Gilead Sciences Inc. said that it expects to launch in the US the production of a number of analogues for its own products. Among the applicants for the release are generic drugs for the treatment of hepatitis ...
24 სექტემბერი 2018
6595
The number of heterosexuals with HIV in Australia is growing - experts

The number of heterosexuals with HIV in Australia is growing - experts

According to the latest statistics published today by the Kirby Institute (University of New South Wales, Australia), the number of diagnoses of "HIV infection" among Australian heterosexual men over the past five years has increased by 10%. The study showed that more than ...
18 სექტემბერი 2018
6533
Scientists: HIV should be considered a major risk factor for cardiovascular disease

Scientists: HIV should be considered a major risk factor for cardiovascular disease

People living with HIV are twice as likely to suffer from cardiovascular disease (CVD), the results of a meta-analysis published in Circulation magazine show. According to researchers, over the past 20 years, the number of CVDs associated with HIV has tripled. Today this ...
17 სექტემბერი 2018
7092
EMA will consider an application for the registration of an antiviral drug dolutegravir / lamivudine

EMA will consider an application for the registration of an antiviral drug dolutegravir / lamivudine

September 14 became known that the pharmaceutical company ViiV Healthcare, part of the GlaxoSmithKline structure, applied to the European Medicines Agency (EMA) for the registration of a two-component antiretroviral dolutegravir / lamivudine intended for the treatment of ...
17 სექტემბერი 2018
8792
HIV-positive Norwegians may not get modern antiretroviral drugs

HIV-positive Norwegians may not get modern antiretroviral drugs

The Kingdom of Norway, which has maintained the status of the state with the world's highest human development index (HDI) for the last ten years and is the third largest on the planet by nominal GDP per capita, is on the verge of a crisis of underfunding the drug people ...
17 სექტემბერი 2018
6565
ViiV submits two-drug regimen for HIV in Europe

ViiV submits two-drug regimen for HIV in Europe

#ViiV Healthcare has submitted an application in Europe for a single-tablet, two-drug regimen of dolutegravir (DTG) and lamivudine (3TC) for the treatment of HIV-1 infection.
3 სექტემბერი 2018
6722
Early birth and weight loss: why Africa refuses dolutegravir?

Early birth and weight loss: why Africa refuses dolutegravir?

Antiretroviral regimens (ART) based on protease inhibitors or nucleoside reverse transcriptase inhibitors can cause early childbirth and low birth weight. This is reported by Aidsmap with reference to the Journal of Acquired Immune Deficiency Syndromes.
31 აგვისტო 2018
7490
FDA approved two new drugs for HIV treatment

FDA approved two new drugs for HIV treatment

The US Food and Drug Administration (FDA) has approved two new drugs for HIV treatment. This happened two months earlier than originally planned. The drugs are suitable for the treatment of adults with the most common strains of the virus and patients who have not received ...
30 აგვისტო 2018
14871
Pharmacies in Finland began to sell rapid tests for HIV

Pharmacies in Finland began to sell rapid tests for HIV

In Finland, kits for testing HIV for blood drop, which can be used at home, were on sale. To get the result you need only wait 15 minutes.
28 აგვისტო 2018
7511
EMA will consider the application for registration of the drug for the treatment of HIV infection Trogarzo

EMA will consider the application for registration of the drug for the treatment of HIV infection Trogarzo

On Tuesday, August 28, the Canadian pharmaceutical company Theratechnologies announced the filing of documents for the registration of the innovative drug for the treatment of HIV-1 with multiple drug resistance (MDR HIV-1) Trogarzo (ibalizumab) to the European Medicines ...
ჩვენ ვიყენებთ ქუქის, რათა გავაუმჯობესოთ თქვენ მიერ საიტის მოხმარება
ვებ-გვერდზე ნებისმიერ ღილაკზე დაჭერით თქვენ გვაძლევთ უფლებას, რომ გამოვიყენოთ თქვენი cookies.